Date posted: July 25, 2017, 6:00 am
In this episode, we discuss the history of ergot products for treatment of migraines. We compare their safety and efficacy to newer agents such as the triptans and assess their resultant place in therapy.
Date posted: July 4, 2017, 6:00 am
In this episode, we discuss several aspects of serotonin syndrome including the typical clinical presentation, its etiology and common drug-induced combinations, and how to appropriately manage the syndrome.
Date posted: June 13, 2017, 6:00 am
In this episode, we discuss the pathophysiology of embolic stroke in patients with atrial fibrillation and review the use of left atrial occlusion devices, such as the WATCHMAN device, to reduce the risk of stroke in patients with atrial fibrillation without the use of anticoagulants like warfarin.
Date posted: May 23, 2017, 6:00 am
In this episode, we review the 12 recommendations from the 2016 CDC Guideline for Prescribing Opioids for Chronic Pain. These recommendations are intended to help curb the opioid epidemic and provide guidance to healthcare providers regarding safer use of opioid therapy.
Date posted: May 2, 2017, 6:00 am
In this episode, we discuss the concept of professional advocacy, with a particular focus on how to advocate for the profession of pharmacy and what tools and organizations are available to assist in being an advocate.
Date posted: April 11, 2017, 6:00 am
In this episode, we discuss with Dr. Megan Hartranft the five oncology drugs that every pharmacist should know about, which is a great review for P4 students who are currently preparing for the NAPLEX. We cover cyclophosphamide, cisplatin, methotrexate, doxorubicin, and vincristine.
Date posted: March 21, 2017, 6:00 am
In this episode, we discuss the newest definition of sepsis and septic shock according to the Sepsis-3 criteria and the 2016 Surviving Sepsis guidelines. We also review the scoring systems of “qSOFA” and “SOFA” and use a patient case to help demonstrate the new definitions.
Date posted: February 28, 2017, 6:00 am
In this episode, we discuss the overuse of proton pump inhibitor (PPI) therapy and several concerns regarding chronic use of this medication class, including hypomagnesemia, fracture risk, low serum B12 levels, anemias, and increased risk of certain infections.
Date posted: February 7, 2017, 6:00 am
In this episode, we discuss the new FDA categorizations of biosimilars, the legal implications of biologic/biosimilar prescriptions, and the new "follow-on" approval pathway of Basaglar, a new insulin glargine U-100 product.
Date posted: January 17, 2017, 6:00 am
In this episode, we discuss the SPRINT trial (intensive vs. standard blood pressure control) using a case vignette of Mr. Wilson, a 55 year old patient presenting to a clinic with a blood pressure of 139/89 mmHg.